TrialThe Lancet. Respiratory medicine2022

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.

ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.